87 results about "Muscle weakness" patented technology

A portable therapeutic exercise device is disclosed for strengthening leg muscles in patients with severe muscular weakness after bedrest. The device features a lightweight, compact base with longitudinal rails and a moving carriage equipped with an adjustable footplate, cushion, and straps for secure engagement. Resistance cords provide variable tension, and a lumbar bolster with an adjustable strap stabilizes the base. A distance sensor and Bluetooth-enabled microcontroller relay real-time data to mobile devices for interactive visual biofeedback, including gaming applications. The carriage offers smooth linear motion via bearing wheels with adjustable spacers. Designed for use in hospital beds, chairs, or on the floor, the device provides a safe, adaptable, and engaging solution for rehabilitation exercises.

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

A closed-loop neuromodulation system includes at least one implantable neurostimulator configured to deliver electrical stimulation to a target nerve innervating a muscle; at least one biosignal sensor configured to detect a physiological signal associated with the target muscle, wherein the physiological signal may include an electromyographic (EMG) or electroneurographic (ENG) signal; and a controller operatively coupled to the neurostimulator and the sensor. The controller is configured to receive the physiological signal from the sensor, determine whether the signal satisfies a predefined condition indicative of weakness, strength, fatigue, muscle underactivity, or overstimulation, and, in response to detecting that the condition is satisfied, automatically adjust one or more stimulation parameters selected from amplitude, frequency, pulse width, train duration, or train count.

The invention discloses a method and a system for identifying muscular weakness of a critical patient, and relates to the field of muscular weakness identification. Subjective clinical muscular strength grading of the patient and instrument detection data are integrated, a muscular weakness grade mapping model of multiple parts is established, and the diagnosis accuracy is greatly improved; through a host / guest part mapping model, namely in combination with subjective feeling and objective detection data of a patient, the medullary muscular weakness symptom prone to missed diagnosis in traditional examination can be identified; on the basis of a muscle weakness index data prediction mechanism, a muscle weakness crisis risk can be warned in advance; through a treatment-evaluation-adjustment closed-loop system, dynamic optimization of a medicine scheme is realized, the crisis occurrence rate can be greatly reduced, the dosage of an immunosuppressive agent is reduced, meanwhile, the treatment effect is maintained, and the system is suitable for patient groups managed for a long time; by establishing a mapping system of a part type set and an index grade set, quantitative unified evaluation of different types such as eye muscle type / whole body type and the like is realized, and subjective judgment errors are reduced.

The present invention provides compositions and methods of their use in treating dystroglycanopathy, muscular dystrophy and other disorders. In particular, a method of treating a disorder associated with a mutation or loss of function in a fukutin related protein (FKRP) gene and / or a disorder associated with a defect in glycosylation of α-DG in a subject is provided, comprising administering to the subject an effective amount of a ribitol and a selective estrogen receptor modulator (SERM).

The present invention relates to a composition, for preventing, relieving, or treating a muscle weakness-related disease, comprising a celery seed extract. The celery seed extract according to the present invention causes a few or no side effects by using a natural product, may increase muscle mass and muscle strength to not only prevent muscle weakness but also inhibit weight gain and body fat increase, and may reduce serum lipid profiles and hepatotoxicity markers (GOT and GPT), and thus is expected to be utilized for preventing, relieving, or treating muscle weakness-related diseases, metabolic diseases, liver diseases, or the like.

Disclosed herein is related to a method for extending lifespan and / or delaying aging in a subject; the method comprises administering to the subject with an effective amount of (24S)-3β-hydroxy-5α-stigmastan-6-one, wherein the delaying aging comprises increasing vitality, muscle strength or motor coordination, insulin sensitivity, or basal metabolic rate; and / or reducing muscle weakness, loss of balance, hair graying, kyphosis, or hyperglycemia. Also encompassed in the present disclosure are methods for promoting weight loss or treating type 2 diabetes mellitus in a subject, in which the methods comprise administering to the subject an effective amount of (24S)-3β-hydroxy-5α-stigmastan-6-one.

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The application discloses a gene editing system for constructing a muscle weakness disease model pig nuclear transfer donor cell with a DOK7 gene mutation and application thereof. The application provides application of DOK7-gRNA2 shown in SEQ ID NO: 16, DOK7-gRNA4 shown in SEQ ID NO: 17 and NCN protein in preparation of a kit. The application further provides a method for preparing a recombinant cell, comprising the following steps: co-transfecting a pig cell with DOK7-gRNA2, DOK7-gRNA4 and NCN protein to obtain a recombinant cell. The recombinant cell is a recombinant cell with a mutated DOK7 gene. The use of any of the above kits is to prepare a recombinant cell, to prepare a muscle weakness model pig, to prepare a muscle weakness cell model, a muscle weakness tissue model or a muscle weakness organ model. The application has great application value for research and development of muscle weakness disease drugs and revealing the pathogenesis of the disease.

There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).

The invention relates to application of traditional Chinese medicine herba epimedii, especially an aqueous extract of herba epimedii and epimedin A in prevention and / or improvement of sarcopenia. Compared with a blank control group and a negative control group, the body lengths of the herba epimedii aqueous extract with the concentration of 1 mg / mL, the total flavonoids with the concentration of 0.026 mg / mL, the epimedium A with the concentration of 50 [mu] M, the epimedium B with the concentration of 200 [mu] M, the epimedium C with the concentration of 100 [mu] M, the icariin with the concentration of 200 [mu] M and the icaritin with the concentration of 100 [mu] M are increased by 21.40%, 23.09%, 26.69%, 24.91%, 29.22%, 33.15% and 28.35% respectively. The icariin administration concentration is improved, and the growth promoting effect concentration dependence is obviously enhanced. The body length of the caenorhabditis elegans is increased by 24.19% and even exceeds that of a positive control group. Epimedin A of 50 mu M can effectively increase the body length of caenorhabditis elegans, and other Epimedin A needs higher concentration; 50 [mu] M has the best effect of protecting and relieving the muscular structure. The invention provides a thought for developing medicines for improving dyskinesia and muscle volume reduction, prolonging life, improving muscle fiber atrophy, treating muscle strength decline, tonifying liver and kidney and strengthening muscles and bones, and the medicine is high in safety.

The present invention relates to a thymic tumor microenvironment antigen detection kit and its application in myasthenia gravis evaluation. The thymic tumor microenvironment antigen detection kit includes quantum dot-coupled antibody AchR, quantum dot-coupled antibody Titin, quantum dot-coupled antibody MuSK, quantum dot-coupled antibody LRP4 and quantum dot-coupled antibody RyR; quantum dot staining is performed on thymic tumor tissue sections by the kit, and different antigen staining can be performed on the same tissue section at the same time. There are differences in the expression levels of AchR, Titin, MuSK, LRP4 and RyR antigens in patients with simple thymoma, simple myasthenia gravis and thymoma combined with myasthenia gravis, and this difference can be used to distinguish the cause, course and prognosis of myasthenia gravis. The method of using quantum dots to directly carry specific antibodies eliminates the complex staining link of secondary antibodies and improves work efficiency; and observes its expression level and spatial position.

An object of a system according to an embodiment is to convey warmth of handwritten characters even to a user with weakened muscle strength.SOLUTION: A system according to an embodiment includes a line-of-sight tracking unit, a character generation unit, a writing pressure addition unit, and a fluctuation addition unit. The eye tracking unit tracks the user's eye using the eye input device and identifies the selected character. The character generation unit analyzes the character information specified by the line-of-sight tracking unit, and generates a character based on the style of the past handwritten character of the user. The writing pressure applying section applies a writing pressure to the character generated by the character generating section. The fluctuation addition section adds a fluctuation to the character generated by the character generation section.SELECTED DRAWING: Figure 1

The present invention relates to a method for obtaining a functionally enhanced mitochondria and a use thereof, and specifically, to: a mitochondria isolated from cells overexpressing glutathione synthase; and a use thereof for preventing, alleviating, or treating muscle weakness-related diseases.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

This invention discloses a shoulder joint exerciser, including a shoulder brace and an upper arm brace, with a hinged rod assembly between them to maintain deflection. A first rod hinged to the back of the shoulder brace is rotatably connected to the end of a second rod hinged to the back of the upper arm brace. An electric push rod is rotatably mounted on the first rod, with its output end hinged to the second rod and positioned close to the upper arm brace. The device also includes a worm gear, with worm wheels respectively mounted on the shafts connecting the first and second rods to the shoulder brace and upper arm brace, the worm gear meshing with the worm wheels. This shoulder joint exerciser has a simple structure and is easy and quick to operate. It avoids the pain or secondary injury caused by the arm falling rapidly during arm raising and lowering due to muscle weakness or poor coordination.

The present invention relates to a pharmaceutically acceptable acid addition salt comprising: (i) S-indolylcarbamate; and (ii) an organic acid, wherein the organic acid has: a pKa1 greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, wherein x is 1 to 10, y is 2 to 20, and z is 1 or 2. The pharmaceutically acceptable acid addition salt is used to treat conditions such as cachexia, sarcopenia, neuromuscular disorders, and muscle weakness.

The apelin receptor modulator can improve the physical performance of a human patient, slow the progression of age-related weakness, and can reduce age-related muscle weakness. The present disclosure provides methods of treating muscle disorders using specific classes of apelin receptor modulators (e.g., agonists). The muscle condition may be an age-related muscle condition. Also provided is a method of maintaining and / or increasing muscle mass, muscle function, and / or muscle strength in an elderly subject by administering an apelin receptor modulator. In some embodiments, an apelin receptor modulator (e.g., an agonist) is BGE-105 or a pharmaceutically acceptable salt thereof.

The application relates to the technical field of intelligent medical auxiliary diagnosis and automatic evaluation of nerve functions, in particular to an NIHSS score automatic evaluation system for stroke patients. The system comprises a multi-modal induction and perception unit, which is used as a front-end data inlet and collects patient responses in real time to generate a video stream containing depth and color information and a synchronous audio stream; a dynamic reference calibration unit, which extracts kinematic characteristics to construct an individualized neural reference template; a neural motion frequency spectrum decomposition unit, which generates a frequency spectrum pathological characteristic vector distinguishing muscle weakness and ataxia; a contralateral mirror inhibition analysis unit, which generates compensation and driving confidence representing real neural driving intentions; a cross-modal reflection analysis unit, which generates a sensory pathway integrity index according to the difference in nerve conduction velocity; and a collaborative scoring decision engine, which maps multi-modal characteristics to a standardized NIHSS score. The application effectively eliminates the interference of age and basic physical fitness on the score, and can also provide high-precision comparison references for subsequent abnormality determination of the affected side.

The present invention relates to a pharmaceutical composition for preventing or treating diseases related to muscle weakness, which comprises alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof. When myoblasts are treated with alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof of the present invention, differentiation into myotubes is promoted. Therefore, alverine, 4-hydroxyalverine, a derivative thereof or a pharmaceutically acceptable salt thereof according to the present invention can be effectively used to promote differentiation of myoblasts and prevent or treat diseases related to muscle weakness.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

Methods and compositions for treating a patient suffering from Huntington's disease or treating symptoms thereof are disclosed. The methods comprise administering to the patient an effective amount of a heteroaryl ketone fused aza-naphthane glucocorticoid receptor modulator (GRM) or an octahydro fused aza-naphthane GRM. In an embodiment, the GRM is Dargencolan. In some embodiments, the GRM is zaltile blue. In embodiments, the GRM is administered orally. In some embodiments, the GRM is administered daily; in other embodiments, the GRM is administered in a regimen, such as once every day, once every three days, once per week, or other administration regimen. The symptoms of Huntington's disease that can be treated by the methods described herein include, but are not limited to, motor symptoms (e.g., muscle weakness, posture abnormalities, walking difficulty, dysphagia) and neurological or psychological symptoms (e.g., seizure, amnesia, consciousness disorder, impaired verbal ability, delirium, depression, anxiety).

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as pulmonary hypertension, fibrosis, muscle weakness and atrophy, metabolic disorders and / or cardiometabolic disease, bone damage, and / or low red blood cell levels (such as anemia).

The present invention relates to a writing device for myasthenia patients, comprising a base, an X-sliding assembly is arranged on the base, a Y-sliding assembly is slidably arranged on the X-sliding assembly; a support plate is slidably arranged on the Y-sliding assembly; a support rod is arranged on the support plate, one end of the support rod is connected to a universal movable rod, and an adapter is arranged on the universal movable rod away from one end of the support rod; a pen-holding mechanism is arranged at the lower part of the adapter. The beneficial effects are: the pen can be better supported, which is convenient for myasthenia patients to write; the myasthenia patients can better move their arms, and the arms can be better supported, and the patients can move their arms autonomously, which is conducive to autonomous writing.

The present disclosure relates to methods, uses, compositions, and kits for using testosterones or testosterone derivatives and growth hormone (GH) or GH derivatives to improve muscle mass, muscle strength, or muscle function in a subject, or to reduce fatigue, pain, or obesity. One aspect of the present disclosure relates to combination therapies of testosterones or testosterone derivatives and GH or GH derivatives for treating various disorders associated with muscle wasting or conditions associated with muscle weakness.

The present invention relates to activin receptor IIA type variants and methods of use thereof. The present invention features a polypeptide comprising an extracellular ActRIIa variant. In some embodiments, the polypeptides of the present invention comprise an extracellular ActRIIa variant fused to an Fc domain monomer or part. The invention also features the treatment of diseases and conditions involving muscle weakness and atrophy using said polypeptides, such as Duchenne muscular dystrophy, facial shoulder brachial muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; the present invention relates to pharmaceutical compositions and methods for treating a metabolic disease, such as obesity, type 1 diabetes mellitus or type 2 diabetes mellitus.

To provide an ankle supporter which centralizes a body axis, improves posture balance, distributes local stress on joints and muscles, improves movement efficiency, improves standing, walking and running ability, reduces fatigue to the body, contributes to prevention of injury, rehabilitation, health promotion and improvement of sports performance and is applicable for daily life, sports and medical care by connecting three ring-shaped supporter members to provide tension balance, covering the foot around the foot dorsum, the heel and the ankle around inner and outer malleolus from the sole, fixing and stabilizing a distal tibiofibular joint, a talocrural joint, a subtalar joint, a Chopart's joint and a Lis-Franc's joint, providing stability in all directions from front to back, from left to right and from up to down and compensating for weakened ligaments and muscle weakness.SOLUTION: In a supporter, a member (1) which wraps a periphery of a foot dorsum from a sole, a member (2) which wraps the periphery of a heel, and a member (3) which wraps the periphery of medial / lateral malleoli are connected and are attached to the periphery of a foot.SELECTED DRAWING: Figure 1

To provide a new male climacteric disorder-ameliorating composition using a safe material free from side effects, and to provide a medicine, food and drink containing the composition.SOLUTION: The male climacteric disorder-improving composition contains a treated product of an Agaricus fruit body.SELECTED DRAWING: Figure 13